1-Chloro-2-fluoro-4-methyl-3-propan-2-ylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Chloro-2-fluoro-4-methyl-3-propan-2-ylbenzene
• 英文别名: 1-chloro-2-fluoro-4-methyl-3-propan-2-ylbenzene
• 化学式: C₁₀H₁₂ClF
• 分子量: 186.65
• InChiKey: PXSAHNUFWSJTFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Processes for the preparation of compounds
  申请人：Krishnan Lalitha

  公开号：US20080058521A1

  公开（公告）日：2008-03-06

  The present invention provides improved synthetic methods for the preparation of compounds that modulate proliferation or differentiation in a cell or tissue.

  本发明提供了改进的合成方法，用于制备能够调节细胞或组织增殖或分化的化合物。
• PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
  申请人：HUNG David T.

  公开号：US20100216814A1

  公开（公告）日：2010-08-26

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文揭示了具有刚性基团的吡啶并[4,3-b]吲哚。在一种实施例中，化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚。在另一种实施例中，化合物是具有环烷基，环烯基或杂环基团的吡啶并[4,3-b]吲哚。还提供了包括这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍，精神障碍，神经递质介导的障碍和/或神经元障碍。
• Heterocyclic compounds useful as aurora a selective inhibitors
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US11384066B1

  公开（公告）日：2022-07-12

  Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

  所提供的式 (I) 化合物或其药学上可接受的盐类可用于抑制 Aurora A 的活性和治疗由 Aurora A 介导的癌症。
• DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160340360A1

  公开（公告）日：2016-11-24

  The present invention provides compounds of Formula (V): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
• US9409908B2
  申请人：——

  公开号：US9409908B2

  公开（公告）日：2016-08-09